Janice M. Mehnert, MD, is the interim director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey. As a medical oncologist, Dr. Mehnert specializes in the evaluation and treatment of melanoma as a member of the Cancer Institute's Melanoma and Soft Tissue Oncology Program.

Contact Dr. Mehnert: mehnerja@cinj.rutgers.edu 732-235-6031

---

Phase I Clinical Trials

A Phase I Study of Pazopanib, Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors

The study aims to:

- Determine the safety and tolerability of pazopanib in combination with weekly paclitaxel and weekly carboplatin on Days 1, 8, and 15 every 28 days in patients with advanced solid tumors.
- Determine the maximum tolerated dose (MTD) of pazopanib in combination with weekly paclitaxel and weekly carboplatin on Days 1, 8, and 15 every 28 days in patients with advanced solid tumors.
- Determine the effect of pazopanib on the pharmacokinetics of paclitaxel and carboplatin.

Learn more about this trial

A Phase I Study of SAR245409 in Patients with Solid Tumors or Lymphoma

The study aims to:

- Evaluate the safety and tolerability of SAR245409 administered as a tablet formulation on 2 treatment schedules (once daily [QD] and twice daily [BID] dosing) in patients with solid tumors or lymphoma.
- Evaluate the plasma pharmacokinetics (PK) of oral administration of SAR245409 given as a tablet formulation on QD and BID treatment schedules in patients with solid tumors or lymphoma.
Solid Tumors

The purpose of this study is to evaluate preliminary signals of potential anti-tumor activity of MK-3475 in patients with a given histopathologic type of PD-L1 positive advanced solid tumor based on RECIST 1.1 as determined by the investigator in specific tumor indications.

Other Available Trials

Learn more

A Phase I Trial of MSB0010718C in Melanoma and NSCLC

The study aims to:

- Assess the safety and tolerability of MSB0010718C and to determine the maximum tolerated dose (MTD) of MSB0010718C in subjects with metastatic or locally advanced solid tumors.
- Characterize the pharmacokinetic (PK) profile of MSB0010718C and to correlate exposure with target occupancy.
- Evaluate the immunogenicity of MSB0010718C and to correlate it to exposure and biological activity.

Learn more about this trial

NCI/CTEP #8983: A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer

The study aims to:

- Define the maximum tolerated dose (MTD) of MK-2206 and hydroxychloroquine (HCQ) when used in combination.
- Determine the side effects and activity of MK-2206 and hydroxychloroquine when used in combination.
- Determine if hydroxychloroquine alters the pharmacokinetics of MK-2206 due to a drug-drug interaction.
- Validate biomarkers for autophagy detection.

Learn more about this trial

Phase I FGFR TK Inhibitor with Advanced or Refractory Solid Tumors or Lymphoma (PMI 002)
The study aims to:

- Determine a safe and biologically active Phase II dose (recommended Phase 2 dose [RP2D]) for JNJ-42756493 (Part 1 Dose Escalation).

- Evaluate the feasibility of treating a molecularly-defined subset of subjects with squamous cell lung cancer and subjects with breast cancer with JNJ-42756493 at the RP2D (Part 2 Dose Expansion).

Learn more about this trial

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients.

Learn more